CD274 and cancer: Immune checkpoint inhibitors (ICIs), particularly anti-programmed death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) therapies, have transformed the treatment landscape for various cancer types, including EC and ESCC [8, 9].